

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: DAVID F. WOODWARD, et al.

Examiner:

Serial No.: Pending

Group Art Unit:

Filed: Herewith

For: **NOVEL PROSTAMIDES FOR THE
TREATMENT OF GLAUCOMA AND
RELATED DISEASES**

Irvine, California

INFORMATION DISCLOSURE STATEMENT

Mail Stop: Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant's provide with regard to the above-identified patent application entitled **NOVEL PROSTAMIDES FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES**, one copy of documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached 2 page Information Disclosure Citation (Form PTO-1449).


While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material

documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: November 13, 2003


Brent A. Johnson
Patent Agent
Registration Number 51,851


Please direct all inquiries and correspondence to:

Brent A. Johnson
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4348
Fax: (714) 246-4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that the above-identified documents are being deposited with the United States Postal Service on Nov. 13, 2003 in an envelope as "Express Mail Post Office To Addressee" mailing label number EV295682537US with sufficient postage for Express Mail addressed to MS: Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date Nov 13, 2003

Susan Bartholomew
Name of person mailing paper

Signature of person signing paper

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17605 (AP)	SERIAL NO.: Pending
APPLICANT: DAVID F. WOODWARD, et al.	TITLE: NOVEL PROSTAMIDES FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES
FILING DATE: HEREWITH	GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicabl)
	AA	5,688,819	11/18/97	Woodward, et al.			
	AB	6,376,533	4/23/02	Burk, et al.			
	AC	6,410,591	6/25/02	Burk, et al.			
	AD	6,531,504	3/11/03	Burk, et al.			
	AE	6,538,018	3/25/03	Burk, et al.			
	AF	6,586,462	7/1/03	Burk, et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/n)
	BA						
	BB						
	BC						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Bezuglov, et. al., Synthesis and Biological Evaluation of Novel Amides of Polyunsaturated Fatty Acids with Dopamine, <i>Bioorganic & Medicinal Chemistry Letters</i> 11 (2001), 447-449)
	CB	Bezuglov, V.V., et al. Bioactive Amides of Fatty Acids, <i>Biochemistry</i> (Moscow), Vol. 63, No. 1 1998, pp. 22-30
	CC	Bezuglov, V.V., et al., Arachidonoylcholine and N,N-dimethylaminoethyl arachidonate, new cholinergic compounds, <i>Russian Journal of Bioorganic Chemistry</i> , Vol. 27, No. 3, 2001, pp. 200-203
	CD	Bezuglov, V.V., et al., Stereochemistry of substitution of allylic hydroxyl with fluorine in prostaglandins. <i>Russian Journal of bioorganic Chemistry</i> , Vol. 22, No. 10, 1996, pp. 688-695.
	CE	Bezuglov, V.V., et al., Synthesis of novel coumarin-3-carboxylic acid derivatives as chemical detectors of hydroxyl radicals in biological systems, <i>Russian Journal of Bioorganic Chemistry</i> , Vol. 23, No. 4, 1997, pp. 288-291.

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17605 (AP)	SERIAL NO.: Pending
APPLICANT: DAVID F. WOODWARD, et al.	TITLE: NOVEL PROSTAMIDES FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES
FILING DATE: HEREWITH	GROUP:

	CF	Bisogno, T., et al., N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in broto and in vivo, <i>Biochem J.</i> , 2000, 351, pp. 817-824
	CG	Bito, L.Z., Prostaglandins, other eicosanoids, and their derivatives as potential antiglaucoma agents, Chpt. 20, <i>Applied Pharmacology in the medical treatment of glaucoma</i> , Drance, S.M. et al., NY, Grune & Stratton, 1984, pp 477-505
	CH	Bito, L.Z., Prostaglandins Old concepts and new perspectives, <i>Arch Ophthalmol</i> , Vol 105, pp. 1036-1039 (1987)
	CI	English, D., et al., Messenger functions of phosphatidic acid, <i>Chemistry of physics of lipids</i> , 80, 1996, 117-132.
	CJ	Janusz, J. M. et al., Vanilloids. 1. analogs of capsaicin with antinociceptive and anti-inflammatory activity, <i>J. Med Chem.</i> 1993, 36, 2595-2604
	CK	Kulikov, V.I., et al., Bioactive amide of prostaglandin E1 and ethanolamine plasmalogen analog of platelet-activating factor inhibits several pathways of human platelet aggregation, <i>Biochemistry (Moscow)</i> , Vol. 65, No. 4, 2000 pp 427-430
	CL	Nilsson, S., et al., PGF2 increases uveoscleral outflow, <i>Invest Ophthalmic Vis Sci. (suppl)</i> 284 ARVO Abstracts, 1987
	CM	Siebold, et al., Esterfied prostaglandin shows 'potent' promise, <i>Prodrug</i> , (5) 3 (1989)
	CN	Wartmann, M., et al., The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide, <i>FEBS LETTERS</i> , 359, 1995, 133-136

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.